Unconventional myosin 1c as autoreactive cells apoptosis marker in multiple sclerosis

N.O. Negrych


Comparative analysis to find the new markers of multiple sclerosis (MS) was conducted. The blood serum of multiple sclerosis patients and healthy donors was analyzed for 48 kDa unconventional myosin 1c (48 kDa Myo1c) isoform concentration. Materials and methods. Sixty one patients with multiple sclerosis and 20 healthy donors aged 19–57 years participated in the research. Methods of investigation: clinical (complaints, life and disease history, general and neurological examination), laboratory (identification of 48 kDa Myo1c in the blood serum by consequent serum protein sedimentation, electrophoresis and digital analysis of electrophoregrams; presence of Myo1c was confirmed by Western blot with anti-Myo1c antibodies). Results. In the blood serum of MS patients and healthy donors, 48 kDa Myo1c was identified. The group of MS patients had significantly higher level of serum 48 kDa Myo1c as compared to the control group. Considering the key role of T-lymphocytes in the autoreactive processes, higher level of serum 48 kDa Myo1c, that is present in great amounts in activated lymphocytes, results from increased apoptosis of these cells. The average age of patients with high levels of 48 kDa Myo1c was significantly lower in comparison to the group with decreased level of this protein. There were no significant correlations between 48 kDa Myo1c levels and sex detected. Conclusions. Myo1c plays an important role in MS pathogenesis, and its 48 kDa isoform may be used as an early diagnostic marker of MS, as well as quantitative indicator of apoptosis of activated autoreactive cells that is significant for the evaluation of disease-modifying treatment effectiveness.


multiple sclerosis; apoptosis; marker; unconventional myosin 1c


Lassmann H, Brück W, Lucchinetti CF. The immunopatho­logy of multiple sclerosis: anoverview // Brain Pathol. — 2007. — Vol. 17. — P. 210-8. doi: 10.1111/j.1750-3639.2007.00064.x.

Соколова Л.И. К вопросу о современных методах диагностики и лечения рассеянного склероза // Мед. вестник. — 2008. — № 1. — С. 28-32.

Волошина Н.П., Левченко І.Л. Фармакоекономічне обґрунтування патогенетичного лікування розсіяного склерозу // Міжнародний неврологічний журнал. — 2006. — № 4. — С. 91-98.

Christine Riedhammer and Robert Weissert. Antigenpresentation, autoantigens, and immuneregulation in multiple sclerosis and other autoimmune diseases // Front. Immunol. — 2015. — Vol. 6. — P. 322. doi: 10.3389/fimmu.2015.00322.

Klein L, Klugmann M, Nave KA, Tuohy VK, Kyewski B. Shapingof the auto-reactive T-cell repertoireby a splicevariant of self protein expressed in thymicepithelial cell // Nat Med. — 2000. — Vol. 6. — P. 56-61. doi: 10.1038/71540.

Anderson MS, Venanzi ES, Klein L, et al. Projection of animmunological selfs hadow with in the thymusby the aire proteins // Science. — 2002. — Vol. 298. — P. 1395-401. doi: 10.1126/science.1075958.

Kamradt T, Mitchison NA. Tolerance and autoimmunity // N Engl J Med. — 2001. — Vol. 344. — P. 655-64. doi:10.1056/NEJM200103013440907.

Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune in flammation // J Exp Med. — 2005. — Vol. 201. — P. 233-40. doi: 10.1084/jem.20041257.

Cencioni MT, Santini S, Ruocco G, et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients // Cell Death and Disease. — 2015. — Vol. 6. — P. e1741; doi: 10.1038/cddis.2015.100.

Miljkovic´ D, Spasojevic I. Multiple Sclerosis: Molecular Mechanisms and Therapeutic Opportunities // Antioxid Redox Signal. — 2013. — Vol. 19(18). — P. 2286-334. doi: 10.1089/ars.2012.5068.

Шоробура М.С., Негрич Т.І., Стойка Р.С. Здатність імуноглобулінів сироватки крові хворих на розсіяний склероз різного віку (діти й дорослі особи) впливати на імунокомпетентні клітини // Міжнародний неврологічний журнал. — 2008. — Т. 2(18).

Myronovkij S, Negrych N, Nehrych T, et al. Identification of a 48kDa form of unconventional myosin 1c in blood serum of patients with autoimmunediseases // Biochemistry and Biophysics Reports. — 2016. — Vol. 5. — P. 175-179. doi: 10.1016/j.bbrep.2015.12.001.

Maravillas-Montero J, Gillespie P, Patin~o-Lo´pez G, et al. Myosin 1c participates in Bcelcytoskeletonrearrangements, isrecruited to the immunologic synapse, and contributes to antigenpresentation // J Immunol. — 2011. — Vol. 187(6). — P. 3053-3063. doi: 10.4049/jimmunol.1004018.

Bond LM, Brandstaetter H, Kendrick-Jones J, et al. Functional roles formyosin 1cincellular signaling pathways // Cell Signal. — 2013. — Vol. 5. — P. 229-235. doi: 10.1016/j.cellsig.2012.09.026.

Greicius G, Westerberg L, Davey EJ, et al. Microvilli structures on B lymphocytes: inducible functional domains? // Int. Immunol. — 2004. — Vol. 16. — P. 353-364. doi: 10.1093/intimm/dxh031.

Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteriafor multiple sclerosis: 2010 revisions to the McDonald criteria // Ann Neurol. — 2011. — Vol. 69(2). — P. 292-302. doi: 10.1002/ana.22366.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: anexpanded disability status scale (EDSS) // Neurology. — 1983. — Vol. 33(11). — P. 1444-52. doi: 10.1212/WNL.33.11.1444

Xu G, Shi Y. Apoptosis signaling path ways and lymphocyte homeostasis // Cell Research. — 2007. — Vol. 17. — P. 759-771. doi: 10.1038/cr.2007.52.

Негрич Т.І. Дослідження впливу солумедролу на процес апоптозу при розсіяному склерозі // Укр. мед. часопис. — 2007. — № 3. — С. 54-60.

Евтушенко С.К., Москаленко М.А. Рассеянный склероз у детей. — К., 2009. — 385 с.

Confavreux C, Vukusic S. The clinical course of multiple sclerosis // Handb Clin Neurol. — 2014. — Vol. 122. — P. 343-69. doi: 10.1016/B978-0-444-52001-2.00014-5.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта